Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after non-Hodgkin lymphoma .

There are some serological and clinical criteria that help to detect the stage of MM and predict the patients' prognosis. These criteria include the level of M protein, calcium, haemoglobin, albumin, creatinine, β2-microglobulin and glomerular filtration rate (GFR).

Inclusion Criteria:

1. Patients older than 18 year with newly diagnosed MM.
2. Approval to sign an informed written consent.

Exclusion Criteria:

• 1. Patient younger than 18 years. 2.Refusal to sign an informed written consent.